Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.

Mahalingam D, Espitia CM, Medina EC, Esquivel JA 2nd, Kelly KR, Bearss D, Choy G, Taverna P, Carew JS, Giles FJ, Nawrocki ST.

Br J Cancer. 2011 Nov 8;105(10):1563-73. doi: 10.1038/bjc.2011.426. Epub 2011 Oct 20.

2.

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.

Mahalingam D, Medina EC, Esquivel JA 2nd, Espitia CM, Smith S, Oberheu K, Swords R, Kelly KR, Mita MM, Mita AC, Carew JS, Giles FJ, Nawrocki ST.

Clin Cancer Res. 2010 Jan 1;16(1):141-53. doi: 10.1158/1078-0432.CCR-09-1385. Epub 2009 Dec 22.

3.

Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.

Carew JS, Medina EC, Esquivel JA 2nd, Mahalingam D, Swords R, Kelly K, Zhang H, Huang P, Mita AC, Mita MM, Giles FJ, Nawrocki ST.

J Cell Mol Med. 2010 Oct;14(10):2448-59. doi: 10.1111/j.1582-4934.2009.00832.x.

4.

Structural studies of the Escherichia coli O90 O-antigen polysaccharide.

Ratnayake S, Widmalm G, Weintraub A, Medina EC.

Carbohydr Res. 1994 Oct 17;263(2):209-15.

PMID:
7528639
5.

Structural studies of the O-antigenic polysaccharides of Escherichia coli O3 and the enteroaggregative Escherichia coli strain 17-2.

Medina EC, Widmalm G, Weintraub A, Vial PA, Levine MM, Lindberg AA.

Eur J Biochem. 1994 Aug 15;224(1):191-6.

Supplemental Content

Loading ...
Support Center